225 related articles for article (PubMed ID: 14695825)
1. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity.
Ersmark K; Feierberg I; Bjelic S; Hamelink E; Hackett F; Blackman MJ; Hultén J; Samuelsson B; Aqvist J; Hallberg A
J Med Chem; 2004 Jan; 47(1):110-22. PubMed ID: 14695825
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor binding to the plasmepsin IV aspartic protease from Plasmodium falciparum.
Gutiérrez-de-Terán H; Nervall M; Ersmark K; Liu P; Janka LK; Dunn B; Hallberg A; Aqvist J
Biochemistry; 2006 Sep; 45(35):10529-41. PubMed ID: 16939205
[TBL] [Abstract][Full Text] [Related]
3. Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors.
Luksch T; Chan NS; Brass S; Sotriffer CA; Klebe G; Diederich WE
ChemMedChem; 2008 Sep; 3(9):1323-36. PubMed ID: 18752222
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes.
Nöteberg D; Hamelink E; Hultén J; Wahlgren M; Vrang L; Samuelsson B; Hallberg A
J Med Chem; 2003 Feb; 46(5):734-46. PubMed ID: 12593654
[TBL] [Abstract][Full Text] [Related]
5. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV.
Ersmark K; Nervall M; Gutiérrez-de-Terán H; Hamelink E; Janka LK; Clemente JC; Dunn BM; Gogoll A; Samuelsson B; Qvist J; Hallberg A
Bioorg Med Chem; 2006 Apr; 14(7):2197-208. PubMed ID: 16307884
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II. Use of solid-phase synthesis to explore novel statine motifs.
Johansson PO; Chen Y; Belfrage AK; Blackman MJ; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
J Med Chem; 2004 Jun; 47(13):3353-66. PubMed ID: 15189032
[TBL] [Abstract][Full Text] [Related]
7. High-speed optimization of inhibitors of the malarial proteases plasmepsin I and II.
Nöteberg D; Schaal W; Hamelink E; Vrang L; Larhed M
J Comb Chem; 2003; 5(4):456-64. PubMed ID: 12857114
[TBL] [Abstract][Full Text] [Related]
8. Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents.
Gupta D; Yedidi RS; Varghese S; Kovari LC; Woster PM
J Med Chem; 2010 May; 53(10):4234-47. PubMed ID: 20438064
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamics simulations of the three dimensional model of plasmepsin II-peptidic inhibitor complexes.
Pranav Kumar SK; Kulkarni VM
Drug Des Discov; 2001; 17(4):293-313. PubMed ID: 11765133
[TBL] [Abstract][Full Text] [Related]
10. Computational analysis of plasmepsin IV bound to an allophenylnorstatine inhibitor.
Gutiérrez-de-Terán H; Nervall M; Dunn BM; Clemente JC; Aqvist J
FEBS Lett; 2006 Oct; 580(25):5910-6. PubMed ID: 17045991
[TBL] [Abstract][Full Text] [Related]
11. High antiplasmodial activity of novel plasmepsins I and II inhibitors.
Dell'Agli M; Parapini S; Galli G; Vaiana N; Taramelli D; Sparatore A; Liu P; Dunn BM; Bosisio E; Romeo S
J Med Chem; 2006 Dec; 49(25):7440-9. PubMed ID: 17149873
[TBL] [Abstract][Full Text] [Related]
12. Replacement of isobutyl by trifluoromethyl in pepstatin A selectively affects inhibition of aspartic proteinases.
Binkert C; Frigerio M; Jones A; Meyer S; Pesenti C; Prade L; Viani F; Zanda M
Chembiochem; 2006 Jan; 7(1):181-6. PubMed ID: 16307463
[TBL] [Abstract][Full Text] [Related]
13. Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D.
Dali B; Keita M; Megnassan E; Frecer V; Miertus S
Chem Biol Drug Des; 2012 Apr; 79(4):411-30. PubMed ID: 22129033
[TBL] [Abstract][Full Text] [Related]
14. Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues.
Xie D; Gulnik S; Collins L; Gustchina E; Suvorov L; Erickson JW
Biochemistry; 1997 Dec; 36(51):16166-72. PubMed ID: 9405050
[TBL] [Abstract][Full Text] [Related]
15. Pyrrolidine derivatives as plasmepsin inhibitors: binding mode analysis assisted by molecular dynamics simulations of a highly flexible protein.
Luksch T; Blum A; Klee N; Diederich WE; Sotriffer CA; Klebe G
ChemMedChem; 2010 Mar; 5(3):443-54. PubMed ID: 20112327
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II.
Muthas D; Nöteberg D; Sabnis YA; Hamelink E; Vrang L; Samuelsson B; Karlén A; Hallberg A
Bioorg Med Chem; 2005 Sep; 13(18):5371-90. PubMed ID: 16054370
[TBL] [Abstract][Full Text] [Related]
17. Predicting functional residues in Plasmodium falciparum plasmepsins by combining sequence and structural analysis with molecular dynamics simulations.
Valiente PA; Batista PR; Pupo A; Pons T; Valencia A; Pascutti PG
Proteins; 2008 Nov; 73(2):440-57. PubMed ID: 18442137
[TBL] [Abstract][Full Text] [Related]
18. The potential of P1 site alterations in peptidomimetic protease inhibitors as suggested by virtual screening and explored by the use of C-C-coupling reagents.
Weik S; Luksch T; Evers A; Böttcher J; Sotriffer CA; Hasilik A; Löffler HG; Klebe G; Rademann J
ChemMedChem; 2006 Apr; 1(4):445-57. PubMed ID: 16892380
[TBL] [Abstract][Full Text] [Related]
19. alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases.
Orrling KM; Marzahn MR; Gutiérrez-de-Terán H; Aqvist J; Dunn BM; Larhed M
Bioorg Med Chem; 2009 Aug; 17(16):5933-49. PubMed ID: 19635672
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of potent and selective BACE-1 inhibitors.
Björklund C; Oscarson S; Benkestock K; Borkakoti N; Jansson K; Lindberg J; Vrang L; Hallberg A; Rosenquist A; Samuelsson B
J Med Chem; 2010 Feb; 53(4):1458-64. PubMed ID: 20128595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
